Готові списки джерел за темами / TARGED DRUG DELIVERY

Зміст

Статті в журналах
Дисертації
Книги
Частини книг
Тези доповідей конференцій
Звіти організацій

Добірка наукової літератури з теми "TARGED DRUG DELIVERY"

Автор: Grafiati

Опубліковано: 11 вересня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "TARGED DRUG DELIVERY".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "TARGED DRUG DELIVERY"

Wu, Zhi-Yuan, Cheng-Chang Lee, and Hsiu-Mei Lin. "Hyaluronidase-Responsive Mesoporous Silica Nanoparticles with Dual-Imaging and Dual-Target Function." Cancers 11, no. 5 (May 20, 2019): 697. http://dx.doi.org/10.3390/cancers11050697.

Повний текст джерела

Анотація:

Nanoparticle-based drug delivery systems are among the most popular research topics in recent years. Compared with traditional drug carriers, mesoporous silica nanoparticles (MSN) offer modifiable surfaces, adjustable pore sizes and good biocompatibility. Nanoparticle-based drug delivery systems have become a research direction for many scientists. With the active target factionalized, scientists could deliver drug carriers into cancer cells successfully. However, drugs in cancer cells could elicit drug resistance and induce cell exocytosis. Thus, the drug cannot be delivered to its pharmacological location, such as the nucleus. Therefore, binding the cell membrane and the nuclear target on the nanomaterial so that the anticancer drug can be delivered to its pharmacological action site is our goal. In this study, MSN-EuGd was synthesized by doping Eu3+ and Gd3+ during the synthesis of MSN. The surface of the material was then connected to the TAT peptide as the nucleus target for targeting the cancer nucleus and then loaded with the anticancer drug camptothecin (CPT). Then, the surface of MSN-EuGd was bonded to the hyaluronic acid as an active target and gatekeeper. With this system, it is possible and desirable to achieve dual imaging and dual targeting, as well as to deliver drugs to the cell nucleus under a hyaluronidase-controlled release. The experimental approach is divided into three parts. First, we conferred the material with fluorescent and magnetic dual-imaging property by doping Eu3+ and Gd3+ into the MSN. Second, modification of the cell membrane target molecule and the nucleus target molecule occurred on the surface of the nanoparticle, making the nanoparticle a target drug carrier. Third, the loading of drug molecules into the carrier gave the entire carrier a specific target profile and enabled the ability to treat cancer. In this study, we investigated the basic properties of the drug carrier, including physical properties, chemical properties, and in vitro tests. The result showed that we have successfully designed a drug delivery system that recognizes normal cells and cancer cells and has good anticancer effects.

Стилі APA, Harvard, Vancouver, ISO та ін.

Yang, Xiaosong, Shizhu Chen, Xiao Liu, Miao Yu, and Xiaoguang Liu. "Drug Delivery Based on Nanotechnology for Target Bone Disease." Current Drug Delivery 16, no. 9 (December 4, 2019): 782–92. http://dx.doi.org/10.2174/1567201816666190917123948.

Повний текст джерела

Анотація:

Bone diseases are a serious problem in modern human life. With the coming acceleration of global population ageing, this problem will become more and more serious. Due to the specific physiological characteristics and local microenvironment of bone tissue, it is difficult to deliver drugs to the lesion site. Therefore, the traditional orthopedic medicine scheme has the disadvantages of high drug frequency, large dose and relatively strong side effects. How to target deliver drugs to the bone tissue or even target cells is the focus of the development of new drugs. Nano drug delivery system with a targeting group can realize precise delivery of orthopedic drugs and effectively reduce the systemic toxicity. In addition, the application of bone tissue engineering scaffolds and biomedical materials to realize in situ drug delivery also are research hotspot. In this article, we briefly review the application of nanotechnology in targeted therapies for bone diseases.

Стилі APA, Harvard, Vancouver, ISO та ін.

K Purushotham and K Anie Vijetha. "A review on transdermal drug delivery system." GSC Biological and Pharmaceutical Sciences 22, no. 2 (February 28, 2023): 245–55. http://dx.doi.org/10.30574/gscbps.2023.22.2.0053.

Повний текст джерела

Анотація:

In order to produce systemic effects, transdermal drug delivery systems (TDDS), commonly referred to as "patches," are dosage forms that are intended to spread a therapeutically active amount of medicine across the skin of a patient. Drugs that are applied topically are delivered using transdermal drug delivery devices. These are pharmaceutical preparations of varying sizes, containing one or more active ingredients, intended to be applied to the unbroken skin in order to deliver the active ingredient after passing through the skin barriers, and these avoid first pass metabolism. Today about 74% of drugs are taken orally and are not found effective as desired. To improve efficacy transdermal drug delivery system was emerged. In TDDS the drug easily penetrates into the skin and easily reaches the target site. To get around the problems with medicine delivery via oral route, transdermal drug delivery systems were developed. These systems have been utilized as secure and reliable drug delivery systems since 1981.

Стилі APA, Harvard, Vancouver, ISO та ін.

Langer, R. "DRUG DELIVERY: Drugs on Target." Science 293, no. 5527 (July 6, 2001): 58–59. http://dx.doi.org/10.1126/science.1063273.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Metera, A., E. Dluska, A. Markowska-Radomska,, B. Tudek, T. Fraczyk, and K. Kosicki. "Functionalized Multiple Emulsions as Platforms for Targeted Drug Delivery." International Journal of Chemical Engineering and Applications 8, no. 5 (October 2017): 305–10. http://dx.doi.org/10.18178/ijcea.2017.8.5.675.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Assani, Kaivon, Amy Neidhard-Doll, and Tarun Goswami. "Mechanical properties of nanoparticles in the drug delivery kinetics." Journal of Pharmaceutical and Biopharmaceutical Research 4, no. 1 (2022): 248–55. http://dx.doi.org/10.25082/jpbr.2022.01.002.

Повний текст джерела

Анотація:

Nanoparticle formulation is a recently developed drug delivery technology with enhanced targeting potential. Nanoparticles encapsulate the drug of choice and delivers it to the target via a targeting molecules (ex. antigen) located on the nanoparticle surface. Nanoparticles can even be targeted to deeply penetrating tissue and can be modeled to deliver drugs through the blood brain barrier. These advancements are providing better disease targeting such as to cancer and Alzheimer’s. Various polymers can be manufactured into nanoparticles. The polymers examined in this paper are polycaprolactone (PCL), poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), and poly(glycolic acid) (PGA). The purpose of this study is to analyze the mechanical properties of these polymers to establish drug delivery trends and model pharmacokinetics and biotransport. We found that, in general, as the melting point, elastic modulus and tensile strength increases, the degradation rate also increases. PLA composite material may be an ideal polymer for drug delivery due to its good control of degradation.

Стилі APA, Harvard, Vancouver, ISO та ін.

Pandey, Parijat, Manisha Saini, and Neeta . "Mucoadhesive drug delivery system: an overview." Pharmaceutical and Biological Evaluations 4, no. 4 (August 1, 2017): 183. http://dx.doi.org/10.26510/2394-0859.pbe.2017.29.

Повний текст джерела

Анотація:

The major objective of any dosage form is to deliver an optimum therapeutic amount of active agent to the proper site in the body to attain constant & maintenance of the desired drug concentration. Mucoadhesive drug delivery systems are effective delivery systems with various advantages as compared to other oral controlled release dosage forms in terms of drug delivery at specific sites with prolonged retention time of drugs at target sites. The main advantage of these systems includes avoiding first pass metabolism of the drugs and hence availability of high drug concentration at target site. Oral mucoadhesive systems have potential ability for controlled and extended release profile so as to get better performance and patient compliance. The present manuscript briefly reviews the benefits of mucoadhesive drug delivery systems, mechanisms involved in mucoadhesion, different factors affecting mucoadhesive drug delivery systems.

Стилі APA, Harvard, Vancouver, ISO та ін.

Islam, Nazrul, and Derek Richard. "Inhaled Micro/Nanoparticulate Anticancer Drug Formulations: An Emerging Targeted Drug Delivery Strategy for Lung Cancers." Current Cancer Drug Targets 19, no. 3 (February 14, 2019): 162–78. http://dx.doi.org/10.2174/1568009618666180525083451.

Повний текст джерела

Анотація:

Local delivery of drug to the target organ via inhalation offers enormous benefits in the management of many diseases. Lung cancer is the most common of all cancers and it is the leading cause of death worldwide. Currently available treatment systems (intravenous or oral drug delivery) are not efficient in accumulating the delivered drug into the target tumor cells and are usually associated with various systemic and dose-related adverse effects. The pulmonary drug delivery technology would enable preferential accumulation of drug within the cancer cell and thus be superior to intravenous and oral delivery in reducing cancer cell proliferation and minimising the systemic adverse effects. Site-specific drug delivery via inhalation for the treatment of lung cancer is both feasible and efficient. The inhaled drug delivery system is non-invasive, produces high bioavailability at a low dose and avoids first pass metabolism of the delivered drug. Various anticancer drugs including chemotherapeutics, proteins and genes have been investigated for inhalation in lung cancers with significant outcomes. Pulmonary delivery of drugs from dry powder inhaler (DPI) formulation is stable and has high patient compliance. Herein, we report the potential of pulmonary drug delivery from dry powder inhaler (DPI) formulations inhibiting lung cancer cell proliferation at very low dose with reduced unwanted adverse effects.

Стилі APA, Harvard, Vancouver, ISO та ін.

Tony, Sara M., and Mohamed EA Abdelrahim. "Inhalation Devices and Pulmonary Drug Delivery." Journal of Clinical and Nursing Research 6, no. 3 (May 12, 2022): 54–72. http://dx.doi.org/10.26689/jcnr.v6i3.3908.

Повний текст джерела

Анотація:

Inhaled drug delivery is mainly used to treat pulmonary airway disorders by transporting the drug directly to its targeted location for action. This decreases the dose required to exert a therapeutic effect and minimizes any potential adverse effects. Direct drug delivery to air passages facilitates a faster onset of action; it also minimizes irritation to the stomach, which frequently occurs with oral medications, and prevents the exposure of drugs to pre-systemic metabolism that takes place in the intestine and liver. In addition to that, the lung is regarded as a route for transporting medications throughout the entire body’s blood circulation. The type of medication and the device used to deliver it are both important elements in carrying the drug to its target in the lungs. Different types of inhalation methods are used in inhaled delivery. They differ in the dose delivered, inhalation technique, and other factors. This paper will discuss these factors in more detail.

Стилі APA, Harvard, Vancouver, ISO та ін.

Anitha, P., J. Bhargavi, G. Sravani, B. Aruna, and Ramkanth S. "RECENT PROGRESS OF DENDRIMERS IN DRUG DELIVERY FOR CANCER THERAPY." International Journal of Applied Pharmaceutics 10, no. 5 (September 8, 2018): 34. http://dx.doi.org/10.22159/ijap.2018v10i5.27075.

Повний текст джерела

Анотація:

With the recent advances of nanotechnology, dendrimers are emerging as a highly attractive class of drug delivery vectors for cancer therapy. Dendrimers are multifunctional smart Nanocarriers to deliver one or more therapeutic agent safely and selectively to cancer cells. The high level of control over the synthesis of dendritic architecture makes dendrimers a nearly perfect (spherical) nanocarrier for site-specific drug delivery. The presence of functional groups in the dendrimers exterior also permits the addition of other moieties that can actively target certain diseases which are now widely used as tumor targeting strategies. Drug encapsulation, solubilization and passive targeting also equally contribute to the therapeutic use of dendrimers. Dendrimers are ideal carrier vehicles on cytotoxicity, blood plasma retention time, biodistribution and tumor uptake. In this review we highlight the advantages of dendrimers over conventional chemotherapy, toxicity and its management, following anti-cancer drugs delivered by using dendrimers and recent advances in drug delivery by various types of dendrimers as well as its diagnostic applications.

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "TARGED DRUG DELIVERY"

Foulkes, Broderick M. "Developing novel drug delivery methods for anti-leishmanial drugs." Thesis, Griffith University, 2020. http://hdl.handle.net/10072/393974.

Повний текст джерела

Анотація:

Background: Leishmaniasis is a DNDi listed disease caused by protozoan parasites of the kinetoplastida class. The disease currently spans over 80 countries, across the New World and Old World, potentially affecting 500 million people with 1 million new cases reported annually. Leishmaniasis is a vector-driven disease, utilizing two genus of sand fly, Phlebotomus sand fly is responsible for Old World transmission, whereas the Lutzomyia sand fly is responsible for New World transmission. The two main stages of leishmaniasis, are the diagnostic stage (promastigote in sand fly) and the infective stage (amastigote in mammalian cells). Dependent on strain, geography and location of infection, there are three main forms of leishmaniasis: cutaneous (subdivided into diffuse-cutaneous leishmaniasis (DCL) and disseminated-cutaneous leishmaniasis (DL)); mucocutaneous; and visceral (subdivided into post-kala azar dermal leishmaniasis (PKDL)). The DNDi status of leishmaniasis indicates that the pharmaceutical interest into research and development is shockingly low, resulting in very little progress into new treatments, limited to current therapeutics that suffer from severe toxicities (cardio, nephro, hepato, oto). These issues can be circumvented by utilising liposomal drug-carriers, as part of an increased interest in nanoparticle research across all glycosciences, modifying these drugs to interact better with the target cell or liposomal carrier can be of great benefit. Aims and Objectives: This project investigated the modification of current therapeutics in leishmanial treatment, paromomycin and compare the changes in antimicrobial efficacy. These modifications would revolve around enhanced binding affinity for macrophages and for liposomal carriers. This was achieved by modifying paromomycin at its reactive primary alcohols, using previously explored chemistry to attach long-chain fatty acids (LCFAs) to these reactive groups to create potential prodrugs. These were then subject to comparative kill efficiency studies against S. aureus, P. aeruginosa, and L. donovani DD8 cells in MIC assays and a resazurin based assay. A further objective was to investigate novel drug targets in leishmania, using LCFA-ligase as a potential target, as it has been reported this protein is differentially expressed, showing prominence and a potential for inhibition. This compound was also tested against L. donovani DD8 in the resazurin based assay. Methods: Paromomycin laurate and palmitate-based derivatives were synthesised by simple esterification, and the LCFA directive synthesised tert-butyl (4-(2-(decanesulfonyl)acetamido)butyl)carbamate) (N-Boc DSA) was synthesised by known methods. These compounds were characterised and subjected to MIC assays on S. aureus and P. aeruginosa, and a resazurin-based high content imaging (HCI) assay on axenic amastigotes of L. donovani DD8. Parallel synthesis and testing of neomycin LCFA derivatives were made by Dylan Farr, and tested against the same pathogens, comparatively with paromomycin derivatives. All experiments were conducted in triplicate and quadruplicate, with statistical differences being analysed by two-way analysis of variance (Two-way ANOVA). Values with P<0.05 were considered significant. Results and Discussion: Paromomycin palmitate and dipalmitate were synthesised with preference on dipalmitate testing due to increased binding affinity for liposomal carriers and macrophages. Laurate synthesis was much less effective under a multitude of conditions. Secondary compound Boc-DSA was synthesised for use in conjunction with the paromomycin derivatives. The paromomycin dipalmitate compound was tested against S. aureus and P. aeruginosa, with comparative aminoglycosides: neomycin palmitate, amikacin palmitate, and kanamycin palmitate. Against S. aureus, all compounds showed reduced activity at all concentrations, with paromomycin and amikacin being the least affected. Lower concentrations of antibiotic saw antagonistic effects with the lipid chain synergistically enhancing bacterial growth. P. aeruginosa testing was inconclusive due to increased pyocyanin expression, potentially increasing biofilm aggregation of the bacterial cells, reducing interactable surface-area for the aminoglycosides. Further testing with biofilm disruptors in conjunction may show improved results. Candidates paromomycin dipalmitate, N-Boc DSA, and neomycin palmitate were tested by V.Avery group at GRIDD (Griffith Institute for Drug Discovery) against L. donovani DD8 axenic amastigotes. Results showed <50% activity among derivative candidates, with lower activity even for paromomycin, a known anti-leishmanial agent. Morphological and pathophysiological changes due to geographical variations in leishmanial strains have been reported to have different effects on therapeutic efficacy. Although the reduced activity of the candidates can be noted for the DD8 strain, further testing on a variety of geographically relevant strains may show different activities. Human monocyte cytotoxicity THP-1 assays were performed in conjunction, <50% activity was similarly found for the described compounds. Conclusions and Future Remarks: Overall, the modification of ring-1 C6’ and ring-3 C5’ into a LCFA-derivative via esterification chemistry showed reduced activity at all concentrations against S. aureus, P. aeruginosa, and L. donovani DD8 amastigotes. Similar for comparative aminoglycosides of neomycin, amikacin, and kanamycin, although results against P. aeruginosa indicate potential biofilm aggregation. The reference compounds, including DSA, tested against L. donovani DD8 showed <50% inhibition, this may be indicative of morphological and pathophysiological changes due to geographical differences in the test strain. Future avenues worth pursuing is a range of LCFA-derivatives such as C10,12,14,18 for synergistic studies. The use of biofilm disruptors in conjunction with the reference compounds may improve P. aeruginosa activity, in addition to biofilm disruptors, the addition of surfactants to improve solubility of the LCFAs, these additions may have antagonistic effects and are worth investigating. Further testing among various geographically relevant strains of L. donovani would prove the theory put forth by Stuart et al. and show the efficacy of the reference compound across multiple geographically-dependent strains. Incorporation of the test compounds into liposomes were not achieved within this project, however investigations against the aforementioned L. donovani DD8 amastigotes, and against RAW 264.7 cells using the encapsulated compounds as comparative data is warranted.
Thesis (Masters)
Master of Medical Research (MMedRes)
School of Medical Science
Griffith Health
Full Text

Стилі APA, Harvard, Vancouver, ISO та ін.

Leach, Jeffrey Harold. "Magnetic Targeted Drug Delivery." Thesis, Virginia Tech, 2003. http://hdl.handle.net/10919/31261.

Повний текст джерела

Анотація:

Methods of guiding magnetic particles in a controlled fashion through the arterial system in vivo using external magnetic fields are explored. Included are discussions of applications, magnetic field properties needed to allow guiding based on particle characteristics, hemodynamic forces, the uniformity of field and gradients, variable tissue characteristics, and imaging techniques employed to view these particles while in transport. These factors influence the type of magnetic guidance system that is needed for an effective drug delivery system. This thesis reviews past magnetic drug delivery work, variables, and concepts that needed to be understood for the development of an in vivo magnetic drug delivery system. The results of this thesis are the concise study and review of present methods for guided magnetic particles, aggregate theoretical work to allow proper hypotheses and extrapolations to be made, and experimental applications of these hypotheses to a working magnetic guidance system. The design and characterization of a magnetic guidance system was discussed and built. The restraint for this system that balanced multiple competing variables was primarily an active volume of 0.64 cm3, a workspace clearance of at least an inch on every side, a field of 0.3T, and a local axial gradient of 13 T/m. 3D electromagnetic finite element analysis modeling was performed and compared with experimental results. Drug delivery vehicles, a series of magnetic seeds, were successfully characterized using a vibrating sample magnetometer. Next, the magnetic seed was investigated under various flow conditions in vitro to analyze the effectiveness of the drug delivery system. Finally, the drug delivery system was successfully demonstrated under limiting assumptions of a specific magnetic field and gradient, seed material, a low fluid flow, and a small volume.
Master of Science

Стилі APA, Harvard, Vancouver, ISO та ін.

Wang, Yan. "Peptide-drug conjugate for Her2-targeted drug delivery." Scholarly Commons, 2018. https://scholarlycommons.pacific.edu/uop_etds/3567.

Повний текст джерела

Анотація:

Recent strategies for anticancer drug design have been focused on utilizing antibody as a drug or targeted moiety for targeted drug delivery. Antibody−drug conjugates (ADCs) have become a promising new class of targeted therapeutic agents for treatment of cancer. ADCs are designed to preferentially direct a cytotoxic drug to a cell-surface antigen recognized by an antibody. However, there are some challenges in developing ADCs, such as limited solid tumor penetration, high manufacturing costs and antibody-drug stoichiometry. Smaller molecules such as peptides have been shown to specifically bind to cancer related targets. These peptides can be used to form peptide-drug conjugates (PDCs) to overcome above-mentioned drawbacks presented by ADCs. In this study, it was hypothesized that novel synthesized PDCs can be a strategy for breast cancer therapy. HER2 specific binding peptides, MARAKE and MARSGL, were modified by addition of a cysteine at C-terminus. The modified peptides were coupled with monomethylauristatin E (MMAE) by using maleimidocaproyl (MC) as a non-cleavable linker to form peptide-drug conjugates (YW1, YW2) and maleimidocaproyl-valine-citrulline (MC-VC) as a cleavable linker to form peptide-drug conjugates (YW3 and YW4). The peptides, peptide-drug conjugates and MC-MMAE, MC-VC-MMAE were characterized using ESI-MS and purified by using high-performance liquid chromatography (HPLC). Cellular uptake study was performed to determine binding specificity and internalization of two HER2 specific peptides and cysteine-modified peptides (MARAKEC, MARSGLC). In vitro cell viability assay was conducted to assess the cytotoxicity and determine the targeting specificity as well as the potency of the peptide-drug conjugates. The purity of each compound was greater than 90%. Internalization of both HER2 specific binding peptides and cysteine-modified peptides were significantly higher than random peptides in HER2 over-expressed cell lines, MDA-MB361 and ZR75, while negligible uptake in HER2 negative cell line, HEK293. MC linked PDCs showed similar cytotoxicity as peptide in all cell lines; while MC-VC linked PDCs have higher cytotoxicity than MMAE in HER2 positive cell line and significant lower cytotoxicity than MMAE in normal cell line HEK293. However, PDCs with MC link do not show significant difference in cytotoxicity compared to the peptide in all cell lines. In conclusion, specificity of HER2 binding for both peptides was preserved after modification with cysteine. The derivation of MMAE to link drug and peptide played a crucial role in the anticancer activity. Peptide-MMAE conjugates with cleavable linker showed a promising targeting capability for delivery of MMAE to HER2 overexpressed cancer cells.

Стилі APA, Harvard, Vancouver, ISO та ін.

Kim, Yoo C. "Targeted drug delivery within the eye." Diss., Georgia Institute of Technology, 2013. http://hdl.handle.net/1853/52971.

Повний текст джерела

Анотація:

This work introduces novel approaches to enhance targeting of pharmacotherapies to cornea, ciliary body, choroid, and posterior segment of the eye using microneedles as a drug delivery platform. The first part of the work determines the ability to deliver protein therapeutics into the cornea using coated microneedles to suppress corneal neovascularization in a rabbit model. The data show that highly targeted delivery of the anti-vascular endothelial growth factor protein therapeutic gave a better biological response of suppressing neovascularization with 11,900 times less dosage compared to topical administration. The second part of the research aims to develop novel formulations to target ciliary body and choroid via suprachoroidal delivery. The results show that a strongly non-Newtonian fluid can be used to slow down the spreading of the particles at the injection site up to 2 months. The results also show that a high molecular weight formulation with weakly non-Newtonian fluid can be used to reach 100% coverage of the choroidal surface with a single injection. The third part of the research aims to determine the biological response of targeting anti-glaucoma therapeutics to the ciliary body in a rabbit model. The results show we can achieve 500- to 1000-fold dose sparing by targeted delivery via supraciliary delivery. The fourth and last part of the research aims to develop novel emulsion droplets to target different locations within the eye using a gravity-mediated delivery technique via suprachoroidal space injection. The results show that we can deliver up to 73% of injected polymeric particles posterior to the equator of the eye. Overall this work demonstrates that microneedles have the capability to deliver pharmacotherapies to cornea, ciliary body, choroid, and posterior of the eye in a highly targeted manner and provide significant dose sparing in the rabbit model.

Стилі APA, Harvard, Vancouver, ISO та ін.

Forbes, Zachary Graham Barbee Kenneth A. "Magnetizable implants for targeted drug delivery /." Philadelphia, Pa. : Drexel University, 2005. http://dspace.library.drexel.edu/handle/1860/472.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Baki, Mert. "Bone Marrow Targeted Liposomal Drug Delivery Systems." Master's thesis, METU, 2011. http://etd.lib.metu.edu.tr/upload/12613251/index.pdf.

Повний текст джерела

Анотація:

Homing is the process that stem cells move to their own stem cell niches under the influence of chemokines like stromal-derived factor-1&alpha
(SDF-1&alpha
) upon bone marrow transplantation (BMT). There is a need for increasing homing efficiency after BMT since only 10-15% of the transplanted cells can home to their own niches and a limited amount of donor marrow can be transplanted. In this study, we aimed to develop and characterize bone marrow targeted liposomal SDF-1&alpha
delivery system prepared by extrusion method. Alendronate conjugation was chosen to target the liposomes to bone marrow microenvironment, particularly the endosteal niche. Optimization studies were conducted with the model protein (

Стилі APA, Harvard, Vancouver, ISO та ін.

Woods, Stephen. "Wireless capsule endoscope for targeted drug delivery." Thesis, Imperial College London, 2016. http://hdl.handle.net/10044/1/39241.

Повний текст джерела

Анотація:

The diagnosis and treatment of pathologies of the gastrointestinal (GI) tract are performed routinely by gastroenterologists using endoscopes and colonoscopes, however the small intestinal tract is beyond the reach of these conventional systems. Attempts have been made to access the small intestines with wireless capsule endoscopes (WCE). These pill-sized cameras take pictures of the intestinal wall and then relay them back for evaluation. This practice enables the detection and diagnosis of pathologies of the GI tract such as Crohn's disease, small intestinal tumours such as lymphoma and small intestinal cancer. The problems with these systems are that they have limited diagnostic capabilities and they do not offer the ability to perform therapy to the affected areas leaving only the options of administering large quantities of drugs or surgical intervention. To address the issue of administering therapy in the small intestinal tract this thesis presents an active swallowable microrobotic platform which has novel functionality enabling the microrobot to treat pathologies through a targeted drug delivery system. This thesis first reviews the state-of-the-art in WCE through the evaluation of current and past literature. A review of current practises such as flexible sigmoidoscopy, virtual colonoscopy and wireless capsule endoscopy are presented. The following sections review the state-of-the-art in methods of resisting peristalsis, drug targeting systems and drug delivery. A review of actuators is presented, in the context of WCE, with a view to evaluate their acceptability in adding functionality to current WCEs. The thesis presents a novel biologically-inspired holding mechanism which overcomes the issue of resisting natural peristalsis in the GI tract. An analysis of the two components of peristaltic force, circumferential and longitudinal peristaltic contractions, are presented to ensure correct functionality of the holding mechanism. A detailed analysis of the motorised method employed to deploy the expanding mechanism is described and a 5:1 scale prototype is presented which characterises the gearbox and validates the holding mechanism. The functionality of WCE is further extended by the inclusion of a novel targeting mechanism capable of delivering a metered dose of medication to a target site of interest in the GI tract. A solution to the problem of positioning a needle within a 360 degree envelope, operating the needle and safely retracting the needle in the GI tract is discussed. A comprehensive analysis of the mechanism to manoeuvre the needle is presented and validation of the mechanism is demonstrated through the evaluation of scale prototypes. Finally a drug delivery system is presented which can expel a 1 ml dose of medication, stored onboard the capsule, into the subcutaneous tissue of the GI tract wall. An analysis of the force required to expel the medication in a set period of time is presented and the design and analysis of a variable pitch conical compression spring which will be used to deliver the medication is discussed. A thermo mechanical trigger mechanism is presented which will be employed to release the compressed conical spring. Experimental results using 1:1 scale prototype parts validate the performance of the mechanisms.

Стилі APA, Harvard, Vancouver, ISO та ін.

Sudimack, Moseley Jennifer Jo. "Targeted drug delivery via the folate receptor /." The Ohio State University, 2002. http://rave.ohiolink.edu/etdc/view?acc_num=osu1486459267519529.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Zhou, Zilan. "Engineered Nanoparticle for Targeted and Controlled Drug Delivery." University of Cincinnati / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1505831582487098.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Bhattacharya, Shiladitya. "Novel folate amphiphile conjugates for targeted drug delivery." Scholarly Commons, 2008. https://scholarlycommons.pacific.edu/uop_etds/2360.

Повний текст джерела

Анотація:

Cancer is not only difficult to treat but the patients also suffer from the pain associated with anticancer treatments. Targeted chemotherapeutics can reduce the adverse effects by reducing the dose required for tumor cell kill. Cancers of various origins often have characteristic marker molecules that distinguish them from the normal tissues. Folate receptors are such marker molecules present in ovarian and cervical cancers. The hypothesis for the current study is that amphiphiles constructed out of folic acid, the natural ligand for the folate receptor, can deliver paclitaxel, a chemotherapeutic compound, to folate receptor expressing cancer cells. To test this hypothesis, amphiphilic molecules were synthesized out of folic acid and fatty acids or long chain aliphatic amines. The gamma carboxylic group of folic acid was converted to an N-alkyl substituted amide. The alkyl group had various chain lengths varying from eleven methylene groups to seventeen methylene groups giving rise to a number of amphiphiles. The amphiphiles formed micelles in aqueous solutions. The critical micellization concentrations of the amphiphiles were measured by pyrene fluorescence and were found to be in the range of 10–70μM. HeLa and Caco-2 cells were taken as in vitro tumor models. Folate receptor expression was verified in HeLa and Caco-2 cells by western blot analysis. HeLa showed more than forty fold expression of the receptor when compared to Caco-2 and was chosen as receptor positive cell line while Caco-2 served as a negative control. Uptake of the folate labeled delivery system in the cell lines was tested by a fluorescent probe (aminocoumarin) labeled amphiphile. To test the specificity of the delivery system towards the receptor positive HeLa cells, the receptors were knocked down (70%) by folate receptor specific siRNA. Fluorescent amphiphile uptake in the knockdown cells was comparable to that of the negative control, Caco-2. Finally cytotoxicity studies were performed for paclitaxel formulated with the folate labeled amphiphiles and compared to free drug treatment in HeLa and Caco-2. IC50 values in HeLa for formulations with the folate labeled amphiphiles were ten folds less than those observed for free drug treatment whereas in Caco-2 no significant difference was noted.

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Книги з теми "TARGED DRUG DELIVERY"

L, Audus Kenneth, and Juliano R. L, eds. Targeted drug delivery. Berlin: Springer-Verlag, 1991.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Juliano, Rudolph L., ed. Targeted Drug Delivery. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-75862-1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Sirianni, Rachael W., and Bahareh Behkam, eds. Targeted Drug Delivery. New York, NY: Springer US, 2018. http://dx.doi.org/10.1007/978-1-4939-8661-3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Bae, You Han, Randall J. Mrsny, and Kinam Park, eds. Cancer Targeted Drug Delivery. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-7876-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Rautio, Jarkko. Prodrugs and targeted delivery: Towards better ADME properties. Weinheim, Germany: Wiley-VCH, 2011.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Çapan, Yılmaz, Adem Sahin, and Hayrettin Tonbul. Drug Delivery with Targeted Nanoparticles. New York: Jenny Stanford Publishing, 2021. http://dx.doi.org/10.1201/9781003164739.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

W, Metcalf Brian, and Dillon Susan 1952-, eds. Target validation in drug discovery. Boston, MA: Academic Press, 2006.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

W, Metcalf Brian, and Dillon Susan 1952-, eds. Target validation in drug discovery. Amsterdam: Academic Press, 2007.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

S, Rapaka Rao, National Institutes of Health (U.S.), and National Institute on Drug Abuse. Division of Preclinical Research., eds. Membranes and barriers: Targeted drug delivery. Rockville, MD: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Drug Abuse, Division of Preclinical Research, 1995.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Maiti, Sabyasachi, and Kalyan Kumar Sen, eds. Bio-Targets and Drug Delivery Approaches. Boca Raton : Taylor & Francis, 2017.: CRC Press, 2016. http://dx.doi.org/10.1201/9781315370118.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Частини книг з теми "TARGED DRUG DELIVERY"

Xu, Christine. "Targeted Bioavailability." In Drug Delivery, 49–61. Hoboken, NJ: John Wiley & Sons, Inc, 2016. http://dx.doi.org/10.1002/9781118833322.ch4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Holowka, Eric P., and Sujata K. Bhatia. "Targeted Materials." In Drug Delivery, 177–223. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1998-7_5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Elmer, Jacob, Thrimoorthy Potta, and Kaushal Rege. "Synthesis of Cationic Polymer Libraries for Gene Delivery Using Diglycidyl Ethers." In Targeted Drug Delivery, 3–16. New York, NY: Springer US, 2018. http://dx.doi.org/10.1007/978-1-4939-8661-3_1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Steinbach-Rankins, Jill M., and Michael R. Caplan. "In Vitro Validation of Targeting and Comparison to Mathematical Modeling." In Targeted Drug Delivery, 121–41. New York, NY: Springer US, 2018. http://dx.doi.org/10.1007/978-1-4939-8661-3_10.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Riley, Rachel S., Jilian R. Melamed, and Emily S. Day. "Enzyme-Linked Immunosorbent Assay to Quantify Targeting Molecules on Nanoparticles." In Targeted Drug Delivery, 145–57. New York, NY: Springer US, 2018. http://dx.doi.org/10.1007/978-1-4939-8661-3_11.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

DeWitt, Matthew R., and M. Nichole Rylander. "Tunable Collagen Microfluidic Platform to Study Nanoparticle Transport in the Tumor Microenvironment." In Targeted Drug Delivery, 159–78. New York, NY: Springer US, 2018. http://dx.doi.org/10.1007/978-1-4939-8661-3_12.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

McDaniel, Dylan K., Veronica M. Ringel-Scaia, Sheryl L. Coutermarsh-Ott, and Irving C. Allen. "Utilizing the Lung as a Model to Study Nanoparticle-Based Drug Delivery Systems." In Targeted Drug Delivery, 179–90. New York, NY: Springer US, 2018. http://dx.doi.org/10.1007/978-1-4939-8661-3_13.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

DiPerna, Danielle M., Alesia V. Prakapenka, Eugene P. Chung, and Rachael W. Sirianni. "Non-Enzymatic Tissue Homogenization for Biodistribution Analysis." In Targeted Drug Delivery, 191–99. New York, NY: Springer US, 2018. http://dx.doi.org/10.1007/978-1-4939-8661-3_14.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Schorzman, Allison N., Andrew T. Lucas, John R. Kagel, and William C. Zamboni. "Methods and Study Designs for Characterizing the Pharmacokinetics and Pharmacodynamics of Carrier-Mediated Agents." In Targeted Drug Delivery, 201–28. New York, NY: Springer US, 2018. http://dx.doi.org/10.1007/978-1-4939-8661-3_15.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Wu, Xingwang, Jiangbing Zhou, and Toral R. Patel. "Generation of Ultra-Small PLGA Nanoparticles by Sequential Centrifugation." In Targeted Drug Delivery, 17–24. New York, NY: Springer US, 2018. http://dx.doi.org/10.1007/978-1-4939-8661-3_2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "TARGED DRUG DELIVERY"

Cooper, Daniel B., and Pavlos P. Vlachos. "Parametric Investigation of Magnetic Particle Transport for Targeted Drug Delivery Applications." In ASME 2011 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/sbc2011-53889.

Повний текст джерела

Анотація:

In recent years, there has been significant clinical and research interest in magnetic drug targeting (MDT). MDT allows the targeted delivery of drugs only to the affected sites, alleviating the rest of the body from the potential toxic or other side effects of the drug. The underlying concept of MDT is to attach drugs to small magnetic particles which can then be manipulated by a magnetic field designed to attract the drug carrying particles to the target site [1]. This will lead to increasing localized accumulation of the drug at the target site. MDT can have great implications on pharmaceutical treatments, ranging from oncology to cardiology and beyond [2, 3].

Стилі APA, Harvard, Vancouver, ISO та ін.

Lueshen, Eric, Indu Venugopal, and Andreas Linninger. "Intrathecal Magnetic Drug Targeting: A New Approach to Treating Diseases of the Central Nervous System." In ASME 2013 2nd Global Congress on NanoEngineering for Medicine and Biology. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/nemb2013-93117.

Повний текст джерела

Анотація:

Intrathecal (IT) drug delivery is a standard technique which involves direct injection of drugs into the cerebrospinal fluid (CSF)-filled space within the spinal canal to treat many diseases of the central nervous system. Currently, in order to reach the therapeutic drug concentration at certain locations within the spinal canal, high drug doses are used. With no method to deliver the large drug doses locally, current IT drug delivery treatments are hindered with wide drug distributions throughout the central nervous system (CNS) which cause harmful side effects. In order to overcome the current limitations of IT drug delivery, we have developed the novel method of intrathecal magnetic drug targeting (IT-MDT). Gold-coated magnetite nanoparticles are infused into a physiologically and anatomically relevant in vitro human spine model and then targeted to a specific site using external magnetic fields, resulting in a substantial increase in therapeutic nanoparticle localization at the site of interest. Experiments aiming to determine the effect of key parameters such as magnet strength, duration of magnetic field exposure, location of magnetic field, and ferrous implants on the collection efficiency of our superparamagnetic nanoparticles in the targeting region were performed. Our experiments indicate that intrathecal magnetic drug targeting and implant-assisted IT-MDT are promising techniques for concentrating and localizing drug-functionalized nanoparticles at required target sites within the spinal canal for potential treatment of diseases affecting the central nervous system.

Стилі APA, Harvard, Vancouver, ISO та ін.

Oliveira, Eduardo Felipe da Silva, and Dário César de Oliveira Conceição. "Magnetic drug-carrying nanoparticles in cancer treatments." In II INTERNATIONAL SEVEN MULTIDISCIPLINARY CONGRESS. Seven Congress, 2023. http://dx.doi.org/10.56238/homeinternationalanais-074.

Повний текст джерела

Анотація:

Abstract Magnetic nanoparticles are nanomaterials that are magnetically influenced by an external gradient. The engineering and manipulation of matter at the molecular level presents several advantages in the field of nanomedicine since most biological molecules exist and function at the nanoscale. Magnetic nanoparticles are promising methods for targeted drug delivery that allow for spatially, temporally and dosage-tunable drug release with minimal side effects. The most commonly used magnetic nanoparticles are Magnetite (Fe3O4) and Maghemite (Fe2O3). The function of drug carriers, or "Drugs delivery" is to take the drug to the pharmacological target, reducing the side effects observed in the drugs, also reducing the amount of drug administered, thus obtaining the pharmacological treatment in an optimized way. This study aims to analyze the use of drug-loading magnetic nanoparticles in cancer treatments.

Стилі APA, Harvard, Vancouver, ISO та ін.

Kobayashi, Hisataka. "Near infrared photo-immunotherapy: A newly developed, target cell-specific cancer theranostic technology." In Optical Molecular Probes, Imaging and Drug Delivery. Washington, D.C.: OSA, 2015. http://dx.doi.org/10.1364/omp.2015.om2d.2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Hanley, Taylor, Jenny Mac, Wenbin Tan, and Bahman Anvari. "Functionalized Erythrocyte-derived Optical Nanoparticles to Target Endothelial Cells of Port Wine Stains." In Optical Molecular Probes, Imaging and Drug Delivery. Washington, D.C.: OSA, 2017. http://dx.doi.org/10.1364/omp.2017.omw3d.6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Huda, Kristie, Chengxi Wu, Jaclyn Sider, Sergey Ermilov, and Carolyn Bayer. "Photoacoustic Tomography for Longitudinal Monitoring of Targeted Contrast Agents." In Optical Molecular Probes, Imaging and Drug Delivery. Washington, D.C.: OSA, 2019. http://dx.doi.org/10.1364/omp.2019.ow2d.3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Galstyan, Anzhela, Silke Niemann, Michael Schäfers, Cristian Alejandro Strassert, and Andreas Faust. "Targeted Photoinduced Killing of Bacterial Pathogens: from Chemical Synthesis to Photobiological Application." In Optical Molecular Probes, Imaging and Drug Delivery. Washington, D.C.: OSA, 2015. http://dx.doi.org/10.1364/omp.2015.om2d.4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Saad, Mohammad A., Stacey Grimaldo-Garcia, Leslie Contreras, Allison Sweeney, Scott Selfridge, Robert Pawle, Srivalleesha Mallidi, and Tayyaba Hasan. "Evaluating the imaging and therapeutic performance of a dual function antibody conjugate in head and neck cancer spheroids." In Optical Molecular Probes, Imaging and Drug Delivery. Washington, D.C.: Optica Publishing Group, 2023. http://dx.doi.org/10.1364/omp.2023.ow4e.3.

Повний текст джерела

Анотація:

This study demonstrates the efficacy of a molecular-targeted dual function antibody-based probe in detecting and treating microscopic oral cancer spheroids by a combination of fluorescence and photoacoustic imaging and photoimmunotherapy.

Стилі APA, Harvard, Vancouver, ISO та ін.

Maher, Jason R., Oranat Chuchuen, Angela D. M. Kashuba, David F. Katz, and Adam Wax. "Combined Raman Spectroscopy and Optical Coherence Tomography for Measuring Analytes in Targeted Tissues." In Optical Molecular Probes, Imaging and Drug Delivery. Washington, D.C.: OSA, 2015. http://dx.doi.org/10.1364/omp.2015.om3d.3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Pace, Joshua, Srinivasarao Madduri, Shivakrishna Kallepu, Philip S. Low, and Mark Niedre. "Fluorescent Molecular Labeling and In Vivo Detection of Circulating Tumor Cells in Mice." In Optical Molecular Probes, Imaging and Drug Delivery. Washington, D.C.: Optica Publishing Group, 2023. http://dx.doi.org/10.1364/omp.2023.ow1e.5.

Повний текст джерела

Анотація:

The goal of this research is to develop a method to label, detect, and count circulating tumor cells directly in vivo with an injectable folate-receptor targeted fluorescent molecular probe and near infrared (NIR) light.

Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "TARGED DRUG DELIVERY"

Dotto, Gian P. Peptide-Targeted Drug Delivery to Breast Tumors. Fort Belvoir, VA: Defense Technical Information Center, July 1999. http://dx.doi.org/10.21236/ada373913.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Atif Syed, Atif Syed. Targeted Drug Delivery by using Magnetic Nanoparticles. Experiment, June 2013. http://dx.doi.org/10.18258/0788.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Dotto, Gian P. Peptide-Targeted Drug Delivery to Breast Tumors. Fort Belvoir, VA: Defense Technical Information Center, July 2000. http://dx.doi.org/10.21236/ada392787.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Kaminski, M. D., A. N. Ghebremeskel, L. Nunez, K. E. Kasza, F. Chang, T. H. Chien, P. F. Fisher, et al. Magnetically responsive microparticles for targeted drug and radionuclide delivery. Office of Scientific and Technical Information (OSTI), February 2004. http://dx.doi.org/10.2172/822552.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Shen, Youqing, Maciej Radosz, and William J. Murdoch. Breast Cancer-Targeted Nuclear Drug Delivery Overcoming Drug Resistance for Breast Cancer Chemotherapy. Fort Belvoir, VA: Defense Technical Information Center, September 2011. http://dx.doi.org/10.21236/ada559246.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

McFadden, Ian. Folate-Targeted Proteolytic Macromolecules for Targeted Drug Delivery and Optical Tumor Imaging. Fort Belvoir, VA: Defense Technical Information Center, February 2011. http://dx.doi.org/10.21236/ada552633.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Jo, Seongbong, Han-Joung Cho, Jung-Eun Base, and Vivek K. Garripelli. Hypoxia-sensitive, Multifunctional Nanoparticles for Targeted Drug Delivery to Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2012. http://dx.doi.org/10.21236/ada567915.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Putnam, David. Exploitation of P-glycoprotein Over-expression for Targeted Drug Delivery to Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 2011. http://dx.doi.org/10.21236/ada571769.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Band, Hamid, Srikumar Raja, and Tatiana Bronich. Mechanism-Based Enhanced Delivery of Drug-Loaded Targeted Nanoparticles for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, February 2013. http://dx.doi.org/10.21236/ada577110.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Bronich, Tatiana, Hamid Band, and Srikumar Raja. Mechanism-Based Enhanced Delivery of Drug-Loaded Targeted Nanoparticles for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, February 2013. http://dx.doi.org/10.21236/ada580965.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!